Compositions and methods of treating a T cell mediated disorder
US10933093B2 · kind B2 · utility
0Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 10, 2018 |
| Grant date | Mar 2, 2021 |
| Priority date | — |
| Expiry date | Apr 10, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/998
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of generating a CD4+FoxP3+ Treg cell, the method includes administering at least one complement antagonist to a naive CD4+ T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4+ T cell, induce TGF-β1 expression of the CD4+ T cell, and induce differentiation of the of the naive CD4+ T cell into a CD4+FoxP3+ Treg cell.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.